KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

The hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tract, spleen, and/or liver, caused by an activating KIT mutation in the KIT gene.

Related Keywords

Texas ,United States ,Houston ,American ,Avapritinib Ayvakit ,Prithviraj Bose ,Midostaurin Rydapt ,International Working Group ,American Society Of Hematology Annual Meeting ,University Of Texas Md Anderson Cancer Center ,International Consensus Classification Of Myeloid Neoplasms ,Blueprint Medicines Corp ,Touchstone Sm Patient ,Iwg Myeloproliferative Neoplasms Research ,European Competence Network On Mastocytosis ,World Health Organization Classification Of Haematolymphoid Tumours ,World Health Organization ,Meeting Of The Society Hematologic Oncology ,Novartis ,International Consensus Classification ,Myeloid Neoplasms ,European Competence Network ,Annual Meeting ,Hematologic Oncology ,Cancer Center ,Myeloproliferative Neoplasms Research ,Cogent Biosciences ,Hematology Annual Meeting ,Acute Leukemias ,World Health Organization Classification ,Haematolymphoid Tumours ,Society Of Hematologic Oncology Annual Meeting Soho ,News ,Myeloproliferative Neoplasms ,Bmpn ,